Acasti Pharma Inc. (NASDAQ: ACST) (TSX-V: ACST) stock plunged more than 22% in the premarketing today after the news that, since obtaining a subpoena from IIROC Company needs to clarify that it’s management and Board of Directors are unsure of any radical change in the company’s activities that will account for the sudden uptick in market activity.
The company has a monthly performance of 87.40%, compared to its half year performance of -28.09%. The biotech firm has 32 employees on its payroll and a Market capitalization of 41.66M. The price of the stock was trading -25.16% away from its 200-day simple moving average.
Discover Tomorrow's Stocks Today!
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
- Tags: Acasti, Acasti Pharma, Acasti stock, ACST, ACST stock, NASDAQ: ACST, TSX-V: ACST
